Ingredient
Dipeptide-2
Dipeptide-2 is an emerging eye-care peptide associated with under-eye puffiness, fluid retention and tired-looking eyes. It is a key active in Croda’s Eyeliss™ peptide complex and fits the 2026 trend toward targeted eye-area anti-aging and fast-acting…
Dipeptide-2 is an emerging eye-care peptide associated with under-eye puffiness, fluid retention and tired-looking eyes. It is a key active in Croda’s Eyeliss™ peptide complex and fits the 2026 trend toward targeted eye-area anti-aging and fast-acting “de-puffing” skincare.
Trend evidence
Dipeptide-2 is one of the two key peptides in Eyeliss™. Research describes Val-Trp/Dipeptide-2 as an ACE-inhibiting peptide relevant to fluid retention and under-eye edema. Its strongest commercial positioning is targeted eye care rather than general full-face anti-aging.
What it does
Reduces the appearance of under-eye puffiness and bags; supports microcirculation and lymphatic drainage; helps improve the appearance of tired-looking eyes; supports eye-contour conditioning and anti-aging care.
Notes
Biological / industrial source: Synthetic cosmetic peptide. Dipeptide-2 is a Valine-Tryptophan (Val-Trp / VW) dipeptide designed for topical cosmetic applications.
R&D / ingredient: Croda Beauty / Sederma — Eyeliss™ peptide complex. Eyeliss™ combines Dipeptide-2 with Palmitoyl Tetrapeptide-7 and Hesperidin Methyl Chalcone.
Developer / supplier: Croda Beauty / Sederma; cosmetic peptide suppliers also manufacture Dipeptide-2 as a standalone ingredient.
Origin: France / Europe; commercially supplied globally.
Representative product: Peter Thomas Roth Instant FIRMx Eye Temporary Eye Tightener; Croda Eyeliss™ is the representative cosmetic raw-material complex.
Approx. retail price: US$100–500+ per 50–100 g for specialty cosmetic active complexes; finished eye-care products containing Dipeptide-2 typically retail around US$30–100+.
Evidence maturity: Medium — established cosmetic ingredient with in-vitro/mechanistic evidence and widespread formulation use, but limited high-quality independent clinical evidence for Dipeptide-2 alone.
Publishing notes: Strongest commercial positioning is targeted eye care / de-puffing.
